Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 6, 2009, Pages 1049-1063

  Bulitta, Jürgen B ^a   Zhao, Ping ^b   Arnold, Robert D ^a,f   Kessler, Dean R ^b   Daifuku, Richard ^b   Pratt, James ^b   Luciano, Gabriel ^b   Hanauske, Axel R ^c   Gelderblom, Hans ^d   Awada, Ahmad ^e   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b Sonus Pharmaceuticals   (United States)

^c DEPARTMENT OF CARDIOLOGY   (Germany)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e JULES BORDET INSTITUTE   (Belgium)

^f UNIVERSITY OF GEORGIA   (United States)

Author keywords

Mechanistic modeling; Non hematological malignancies; NONMEM; Paclitaxel; Population pharmacokinetics; Solubility limited disposition model; Ultrafiltration

Indexed keywords

CREMOPHOR; PACLITAXEL; PACLITAXEL TOCOSOL;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIGESTIVE SYSTEM CANCER; DRUG CLEARANCE; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; HEAD AND NECK CANCER; HUMAN; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MULTICENTER STUDY; NANODROPLET FORMULATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; ULTRAFILTRATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LEUKOCYTE COUNT; LINEAR MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; NANOPARTICLES; NEOPLASMS; PACLITAXEL; STRUCTURE-ACTIVITY RELATIONSHIP; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 63949086668     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0827-2     Document Type: Article

References (47)

1. Beal SL, Sheiner LB, Boeckmann AJ (2006) NONMEM Users Guides (1989-2006). Icon Development Solutions, Ellicott City
2. DJ Brat AJ Windebank S Brimijoin 1992 Emulsifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma J Pharmacol Exp Ther 261 803 810
3. E Brouwer J Verweij P De Bruijn WJ Loos M Pillay D Buijs A Sparreboom 2000 Measurement of fraction unbound paclitaxel in human plasma Drug Metab Dispos 28 1141 1145
4. T Brown K Havlin G Weiss J Cagnola J Koeller J Kuhn J Rizzo J Craig J Phillips D Von Hoff 1991 A phase I trial of taxol given by a 6-hour intravenous infusion J Clin Oncol 9 1261 1267
5. PP Constantinides KJ Lambert AK Tustian B Schneider S Lalji W Ma B Wentzel D Kessler D Worah SC Quay 2000 Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel Pharm Res 17 175 182
6. PP Constantinides A Tustian DR Kessler 2004 Tocol emulsions for drug solubilization and parenteral delivery Adv Drug Deliv Rev 56 1243 1255
7. AB Dhanikula R Panchagnula I Singh KJ Kaur CL Kaul JS Sekhon 2001 Pharmacokinetic study of paclitaxel as a 3-hour infusion in an Indian population: 135 mg/m2 vs. 175 mg/m2 Methods Find Exp Clin Pharmacol 23 93 98
8. RT Dorr 1994 Pharmacology and toxicology of Cremophor EL diluent Ann Pharmacother 28 S11 S14
9. H Gelderblom K Mross AJ ten Tije D Behringer S Mielke DM van Zomeren J Verweij A Sparreboom 2002 Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions J Clin Oncol 20 574 581
10. H Gelderblom J Verweij E Brouwer M Pillay P de Bruijn K Nooter G Stoter A Sparreboom 1999 Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function Drug Metab Dispos 27 1300 1305
11. L Gianni CM Kearns A Giani G Capri L Vigano A Lacatelli G Bonadonna MJ Egorin 1995 Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans J Clin Oncol 13 180 190
12. H Hamada K Ishihara N Masuoka K Mikuni N Nakajima 2006 Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrins J Biosci Bioeng 102 369 371
13. G Hempel C Rube C Mosler M Wienstroer A Wagner-Bohn A Schuck N Willich J Boos 2003 Population pharmacokinetics of low-dose paclitaxel in patients with brain tumors Anticancer Drugs 14 417 422
14. A Henningsson MO Karlsson L Vigano L Gianni J Verweij A Sparreboom 2001 Mechanism-based pharmacokinetic model for paclitaxel J Clin Oncol 19 4065 4073
15. A Henningsson S Marsh WJ Loos MO Karlsson A Garsa K Mross S Mielke L Vigano A Locatelli J Verweij A Sparreboom HL McLeod 2005 Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel Clin Cancer Res 11 8097 8104
16. A Henningsson A Sparreboom M Sandstrom A Freijs R Larsson J Bergh P Nygren MO Karlsson 2003 Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients Eur J Cancer 39 1105 1114
17. NK Ibrahim N Desai S Legha P Soon-Shiong RL Theriault E Rivera B Esmaeli SE Ring A Bedikian GN Hortobagyi JA Ellerhorst 2002 Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel Clin Cancer Res 8 1038 1044
18. M Joerger AD Huitema DH van den Bongard JH Schellens JH Beijnen 2006 Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors Clin Cancer Res 12 2150 2157
19. MO Karlsson V Molnar A Freijs P Nygren J Bergh R Larsson 1999 Pharmacokinetic models for the saturable distribution of paclitaxel Drug Metab Dispos 27 1220 1223
20. CM Kearns L Gianni MJ Egorin 1995 Paclitaxel pharmacokinetics and pharmacodynamics Semin Oncol 22 16 23
21. D Kessel 1992 Properties of cremophor EL micelles probed by fluorescence Photochem Photobiol 56 447 451
22. GN Kumar UK Walle KN Bhalla T Walle 1993 Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein Res Commun Chem Pathol Pharmacol 80 337 344
23. B Monsarrat P Alvinerie M Wright J Dubois F Gueritte-Voegelein D Guenard RC Donehower EK Rowinsky 1993 Hepatic metabolism and biliary excretion of Taxol in rats and humans J Natl Cancer Inst Monogr 15 39 46
24. RD Mosteller 1987 Simplified calculation of body-surface area N Engl J Med 317 1098
25. DR Mould GF Fleming KM Darcy D Spriggs 2006 Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study Br J Clin Pharmacol 62 56 70
26. MM Oken RH Creech DC Tormey J Horton TE Davis ET McFadden PP Carbone 1982 Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 649 655
27. EK Rowinsky EA Eisenhauer V Chaudhry SG Arbuck RC Donehower 1993 Clinical toxicities encountered with paclitaxel (Taxol) Semin Oncol 20 1 15
28. P Sapra P Tyagi TM Allen 2005 Ligand-targeted liposomes for cancer treatment Curr Drug Deliv 2 369 381
29. US Sharma SV Balasubramanian RM Straubinger 1995 Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins J Pharm Sci 84 1223 1230
30. DS Sonnichsen CA Hurwitz CB Pratt JJ Shuster MV Relling 1994 Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors J Clin Oncol 12 532 538
31. A Sparreboom WJ Loos J Verweij AI de Vos ME van der Burg G Stoter K Nooter 1998 Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay Anal Biochem 255 171 175
32. A Sparreboom O van Tellingen WJ Nooijen JH Beijnen 1996 Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL Cancer Res 56 2112 2115
33. A Sparreboom O van Tellingen WJ Nooijen JH Beijnen 1996 Tissue distribution, metabolism and excretion of paclitaxel in mice Anticancer Drugs 7 78 86
34. A Sparreboom L van Zuylen E Brouwer WJ Loos P de Bruijn H Gelderblom M Pillay K Nooter G Stoter J Verweij 1999 Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications Cancer Res 59 1454 1457
35. A Sparreboom J Verweij ME van der Burg WJ Loos E Brouwer L Vigano A Locatelli AI de Vos K Nooter G Stoter L Gianni 1998 Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo Clin Cancer Res 4 1937 1942
36. Spigel SC, Jones SF, Greco FA (2002) S-8184 vitamin E paclitaxel emulsion: preclinical and phase 1 data. Proc Am Soc Clin Oncol 21. Abstract no. 406
37. RM Straubinger SV Balasubramanian 2005 Preparation and characterization of taxane-containing liposomes Methods Enzymol 391 97 117
38. HJ van den Bongard RA Mathot O van Tellingen JH Schellens JH Beijnen 2002 A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling Cancer Chemother Pharmacol 50 16 24
39. O van Tellingen JH Beijnen J Verweij EJ Scherrenburg WJ Nooijen A Sparreboom 1999 Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice Clin Cancer Res 5 2918 2924
40. O van Tellingen MT Huizing VR Panday JH Schellens WJ Nooijen JH Beijnen 1999 Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients Br J Cancer 81 330 335
41. L van Zuylen MO Karlsson J Verweij E Brouwer P de Bruijn K Nooter G Stoter A Sparreboom 2001 Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles Cancer Chemother Pharmacol 47 309 318
42. L van Zuylen J Verweij A Sparreboom 2001 Role of formulation vehicles in taxane pharmacology Invest New Drugs 19 125 141
43. T Walle UK Walle GN Kumar KN Bhalla 1995 Taxol metabolism and disposition in cancer patients Drug Metab Dispos 23 506 512
44. RB Weiss RC Donehower PH Wiernik T Ohnuma RJ Gralla DL Trump JR Baker Jr DA Van Echo DD Von Hoff B Leyland-Jones 1990 Hypersensitivity reactions from taxol J Clin Oncol 8 1263 1268
45. PH Wiernik EL Schwartz A Einzig JJ Strauman RB Lipton JP Dutcher 1987 Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma J Clin Oncol 5 1232 1239
46. MD Wild UK Walle T Walle 1995 Extensive and saturable accumulation of paclitaxel by the human platelet Cancer Chemother Pharmacol 36 41 44
47. AJ Windebank MD Blexrud PC de Groen 1994 Potential neurotoxicity of the solvent vehicle for cyclosporine J Pharmacol Exp Ther 268 1051 1056